ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,675.12
0.64%
US Tech 100
19,301.60
0.60%
다우존스 지수
41,841.63
0.85%
Bitcoin
83,001.73
-1.26%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Precision BioSciences Inc (DTIL) 시세

Precision BioSciences Inc

Precision BioSciences Inc (DTIL)

NASDAQ
5.05
0.01
(0.20%)
마감 18 3월 5:00AM
15분 지연
4.99
-0.06
(-1.19%)
시간외 거래: 8:59AM
15분 지연

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

프리미엄

주요 통계 및 세부정보

가격
5.05
매수가
4.99
매도가
5.13
거래량
195,604
4.95 일간 변동폭 5.475
3.61 52주 범위 15.97
market_cap
38.739M
전일 종가
5.04
개장가
5.475
최근 거래 시간
4
@
5.05
마지막 거래 시간
재정 규모
US$ 1,001,881
VWAP
5.122
평균 볼륨(3m)
523,735
발행 주식
7,671,059
배당수익률
-
주가수익률
-0.63
주당순이익(EPS)
-7.99
매출
48.73M
순이익
-61.32M

Precision BioSciences Inc 정보

Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The company's segment... Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The company's segments include Therapeutics and Food out of which the Therapeutics segment act as a key revenue driver for the firm. 더 보기

섹터
Biological Pds,ex Diagnstics
산업
Biological Pds,ex Diagnstics
웹사이트
www.precisionbiosciences.com
본부
Wilmington, Delaware, USA
설립됨
-
Precision BioSciences Inc is listed in the Biological Pds,ex Diagnstics sector of the 나스닥 with ticker DTIL. The last closing price for Precision BioSciences was US$5.04. Over the last year, Precision BioSciences shares have traded in a share price range of US$ 3.61 to US$ 15.97.

Precision BioSciences currently has 7,671,059 shares in issue. The market capitalisation of Precision BioSciences is US$38.66 million. Precision BioSciences has a price to earnings ratio (PE ratio) of -0.63.

DTIL 최신 뉴스

추가 뉴스

Form 8-K - Current report
Edgar (US Regulatory)
08 3월 2025
DTIL (0.20%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
06 3월 2025
DTIL (0.20%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
06 3월 2025
DTIL (0.20%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
06 3월 2025
DTIL (0.20%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
06 3월 2025
DTIL (0.20%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
05 3월 2025
DTIL (0.20%)
기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-0.15-2.884615384625.25.34.9490985.0514454CS
4-0.36-6.654343807765.416.14.69011182235.4879042CS
120.388.137044967884.677.43993.615237355.49955763CS
26-5.39-51.628352490410.4410.483.612862965.85064995CS
52-6.45-56.086956521711.515.973.611698266.8159568CS
156-82.25-94.2153493787.3109.23.6183326732.35379425CS
260-150.35-96.7503217503155.44983.61763186114.93800168CS

DTIL - Frequently Asked Questions (FAQ)

What is the current Precision BioSciences share price?
The current share price of Precision BioSciences is US$ 5.05
How many Precision BioSciences shares are in issue?
Precision BioSciences has 7,671,059 shares in issue
What is the market cap of Precision BioSciences?
The market capitalisation of Precision BioSciences is USD 38.66M
What is the 1 year trading range for Precision BioSciences share price?
Precision BioSciences has traded in the range of US$ 3.61 to US$ 15.97 during the past year
What is the PE ratio of Precision BioSciences?
The price to earnings ratio of Precision BioSciences is -0.63
What is the cash to sales ratio of Precision BioSciences?
The cash to sales ratio of Precision BioSciences is 0.79
What is the reporting currency for Precision BioSciences?
Precision BioSciences reports financial results in USD
What is the latest annual turnover for Precision BioSciences?
The latest annual turnover of Precision BioSciences is USD 48.73M
What is the latest annual profit for Precision BioSciences?
The latest annual profit of Precision BioSciences is USD -61.32M
What is the registered address of Precision BioSciences?
The registered address for Precision BioSciences is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Precision BioSciences website address?
The website address for Precision BioSciences is www.precisionbiosciences.com
Which industry sector does Precision BioSciences operate in?
Precision BioSciences operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
ANTEAirNet Technology Inc
US$ 1.6001
(96.72%)
109.76M
SCNXScienture Holdings Inc
US$ 2.5589
(71.74%)
26.79M
VTVTvTv Therapeutics Inc
US$ 23.40
(57.58%)
514.8k
ARQQArqit Quantum Inc
US$ 23.615
(57.43%)
2.86M
MGRMMonogram Technologies Inc
US$ 3.65
(56.65%)
34.2M
BONBon Natural Life Ltd
US$ 0.5926
(-58.85%)
22.96M
LYTLytus Technologies Holdings PTV Ltd
US$ 0.0843
(-24.66%)
190.78M
STBXStarBox Group Holdings Ltd
US$ 0.2032
(-23.81%)
1.72M
COEPCoeptis Therapeutics Holdings Inc
US$ 8.50
(-23.15%)
215.3k
CTORCitius Oncology Inc
US$ 0.572
(-22.07%)
302.8k
NVDANVIDIA Corporation
US$ 119.53
(-1.76%)
257.41M
LYTLytus Technologies Holdings PTV Ltd
US$ 0.0843
(-24.66%)
190.78M
INTCIntel Corporation
US$ 25.69
(6.82%)
160.72M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 8.3401
(-9.54%)
155.72M
TSLATesla Inc
US$ 238.01
(-4.79%)
112.26M

DTIL Discussion

게시물 보기
tw0122 tw0122 2 월 전
Gene editing news $5 to $7s next 
👍️0
Monksdream Monksdream 3 월 전
DTIL under $5
👍️0
Monksdream Monksdream 6 월 전
DTIL under $10
👍️0
Monksdream Monksdream 8 월 전
DTIL under $10
👍️0
jondoeuk jondoeuk 9 월 전
I think they did, but there are still a lot of vampires sucking away at the (limited) revenue.
👍️0
Monksdream Monksdream 11 월 전
DTIL under $10
👍️0
NY1972 NY1972 11 월 전
Why they hired a Chief People Officer instead of of trimming head count? another GNCA IMO
👍️0
jondoeuk jondoeuk 11 월 전
Management can try and spin this as much as they want, but this is a failure https://www.businesswire.com/news/home/20240416117356/en/Precision-BioSciences-Announces-Return-of-Programs-and-Conclusion-of-Collaboration-with-Prevail-Therapeutics
👍️0
jondoeuk jondoeuk 11 월 전
If one of the companies that are developing off-the-shelf succeed, I don't see why any insurer will pay the price tag of an autologous therapy (assuming similar data/success). On paper, it should be easier than oncology.
👍️0
Monksdream Monksdream 1 년 전
DTIL 10Q due March 13
👍️0
jondoeuk jondoeuk 1 년 전
That didn't take long! https://www.businesswire.com/news/home/20240301968620/en/Precision-BioSciences-Announces-40.0-Million-Offering-of-Common-Stock-and-Warrants

Maybe things are going slower on the clinical front or no milestone payments are expected.
👍️0
rtrstock rtrstock 1 년 전
What do you mean an offering?
👍️0
surf1944 surf1944 1 년 전
Precision BioSciences, Inc. (DTIL) will effect a one-for-thirty (1-30) reverse split of its Common Stock. The reverse stock split will become effective on Wednesday, February 14, 2024. In conjunction with the reverse split, the CUSIP number will change to 74019P207

The 1 for 30 R/S will make it easy is come out with an offering in the next week or so.
👍️0
rtrstock rtrstock 1 년 전
1 for 30 not bad, but still will have to hold a long time to get my money back, if I ever do, averaged in at maybe 1.30, so uncertain what price will need to be after reverse split eventually to even break even. Wanting to hold long and make money eventually, but unsure if that's still possible.

I have 5100 shares, so that will be cut to practically nothing, it'd have to go to nearly 50.00 a share for me to make my money back?

Is this correct? Is basically everyone even the big investors like Lilly and Cargill losing big on this one?
👍️0
jondoeuk jondoeuk 1 년 전
Now there will be one. The BOD approved a 1-for-30 R/S. It will become effective at 5:00 p.m. ET on Feb 13. The uncertainty has been eliminated.
👍️0
rtrstock rtrstock 1 년 전
Guess I'll hold even if there is a R/S
👍️0
jondoeuk jondoeuk 1 년 전
I thought they would, but it seems to me that they want to allow the clock to run before they set a R/S. Looking at the filing, it leaves the effective date to the BOD's discretion. It also gives the them the discretion to abandon it. The company has until the 22nd of April for the stock price to attain what is needed, thereby keeping its listing.
👍️0
NY1972 NY1972 1 년 전
Side dish becomes the main course. High paid bio CEOs need another bait and switch.
👍️0
jondoeuk jondoeuk 1 년 전
Autoimmune diseases are clearly the next frontier for CAR-T/NK cell therapies, with numerous biotech and (big) pharma companies in the space https://finance.yahoo.com/news/precision-biosciences-completes-license-deal-120000510.html
👍️ 1
81vette 81vette 1 년 전
Res. Breakout,after hours could get fun
👍️ 1
81vette 81vette 1 년 전
Accumulation at nhod
👍️ 1
81vette 81vette 1 년 전
11th most newly watched ticker,do dd,others are
👍️0
81vette 81vette 1 년 전
The 2.5m buy, should open some eyes
👍️0
81vette 81vette 1 년 전
Death hour is over,mid day vol surge coming,this pennant has gotten pointy/pokey/stabby(technical terms lol)held strong with .4333 last low bounce,demand growing now,waiting for thru .44 to send it higher
👍️0
81vette 81vette 1 년 전
DTIL astronomical potential=greed/hold,tutes own 27%,insiders 21%,100M cash(no offerings),eps this year up 60%/sales past 5years up 102%(tells me sales have started and that explains tutes,I expect they buy more now) 27%below the sma200(so it’s got at least that much run room) target price 2.62, 198 employees,bullish chart since Oct 30th,could be some bashers because it is optionable/shortable,institutional could send this flying up,relative buying vol up 148Xs today ,shares available to short is dropping but still 3.5M(was 4.3m) overall I like that I can put this in my portfolio for long(or until chart breaks) and not have to watch it like a nail biting pump and dump,I have too many of those already lol
👍️0
rtrstock rtrstock 1 년 전
What indication of a RS is there? Or is it assumed?

This looks like a good buy to me, am I wrong?
👍️0
NY1972 NY1972 1 년 전
Plenty dead bios walking in this mkt. still handing out options like clock work.
👍️0
NY1972 NY1972 1 년 전
This bio is walking dead. Failure to let go the PhDs and CARTs a few years ago costed hundreds millions. ARCUS will be bought by IECure after the cash dries up.
👍️0
jondoeuk jondoeuk 1 년 전
Yes, but I think the R/S will happen.
👍️0
Sirpeter Sirpeter 1 년 전
There's still time
👍️0
jondoeuk jondoeuk 1 년 전
So, at 4:30pm the day before Thanksgiving, they announce a special meeting to vote on a R/S. It will take place on Thurs, Jan 18, '24, at 11:00 am, Eastern Time, at a ratio ranging from 1-for-10 and 1-for-30.
👍️0
Sirpeter Sirpeter 1 년 전
Moving up nicely...looks good
👍️0
knrorrel knrorrel 1 년 전
nice chart, bottom now and here, Now get the news out and let's see what happens, maybe we'll almost never see these low prices down here on the ground again.
imho
👍️0
knrorrel knrorrel 1 년 전
News Out, should running hard in good News
imho
👍️0
knrorrel knrorrel 1 년 전
a really nice $DTIL News https://ih.advfn.com/stock-market/NASDAQ/precision-biosciences-DTIL/stock-news/92484281/precision-biosciences-reports-third-quarter-2023-f


👍️0
rtrstock rtrstock 1 년 전
Well on stock twits they are saying there is no filed reverse split and that they are expecting an extension to be filed, so I hope you are right. I'm uncertain what all is going on, but I like what this company is doing with it's aspirations in medicine, so staying with it. Just accumulated more, lowered my average cost.
👍️0
konshe konshe 1 년 전
bottom rebound coming, time to buy.
👍️ 1
Monksdream Monksdream 1 년 전
DTIL new 52 week low
👍️0
Monksdream Monksdream 1 년 전
DTIL new 52 week low
👍️0
Monksdream Monksdream 1 년 전
DTIL new 52 wewek low
👍️0
NY1972 NY1972 2 년 전
DTIL founders never worried about cash until the meltdown. They hired too many PhDs, built fancy expensive labs with lots of promises. They never tried to trim the expenses to make sure there will be cash left for clinical trials. High burn and lots of GT bios spell doom for this bio.
👍️0
jondoeuk jondoeuk 2 년 전
I should have pointed out that companies are happening to develop small[er] nucleases. Here is one paper from Casebia Therapeutics, which is a joint venture between CRSP and BAYN https://www.nature.com/articles/s41467-021-24454-5

Also, in 2020, researchers led by Dr. Liu created a new base editor that could perform C-to-T conversion of DNA in mitochondria. However, it had limitations, not only being restricted to that conversion, but mostly limited a certain motif. This means that it could correct only 10% of confirmed pathogenic mitochondrial point mutations https://www.nature.com/articles/s41587-022-01256-8

Last year another novel base editor was created that could achieve A-to-G conversion. Being able to perform that could correct 43% of confirmed pathogenic mitochondrial point mutations https://www.cell.com/cell/fulltext/S0092-8674(22)00389-0

However, I don't see either base editor entering the clinic for a number of years.
👍️0
jondoeuk jondoeuk 2 년 전
Or it could end up like TRIL. ARCUS has some benefits over current CRISPR systems, manly its size, can edit the mitochondrial genome and IP is not a mess.
👍️0
NY1972 NY1972 2 년 전
IECure will buy the ARCUS IP when cash is 0 in 18 months.
👍️0
jondoeuk jondoeuk 2 년 전
Not the most productive use of its cash so far. The R&D Day could change that, but the market doesn't seem to think it.
👍️0
NY1972 NY1972 2 년 전
this is a homeless shelter for PhDs. Cash is not spent on patients. They hired a chief people officer to cut the pie.
👍️0
jondoeuk jondoeuk 2 년 전
The market did not find the recent announcement attractive https://www.businesswire.com/news/home/20230815091930/en/Precision-BioSciences-Completes-Strategic-Transaction-with-Imugene-for-Azer-Cel-in-Cancer

I think a reverse split is a possibility, especially after the announcement couldn't move the PPS. If that happens, will likely add fuel to any downward price pressure. Management don't seem the best. Now it's do or die with the in vivo programs.
👍️0
rtrstock rtrstock 2 년 전
That's what I'm afraid of, guess I'll just wait. Keep my shares.
👍️0
J-mak J-mak 2 년 전
In my opinon slim very very slim
👍️0
rtrstock rtrstock 2 년 전
What's the educated guess?

What's realistically possible by October date for pps to be more than $1.00
👍️0

최근 히스토리

NASDAQ
DTIL
Precision BioSciences
NASDAQ
CASBX
Capital Group Internatio...
EU
ROCK
Whitestone
TG
P2SC
ProShares UltraPro MidCa...
LSE
RH07
Silverstne.70 A
NASDAQ
CBKQX
Ci Canadian All Cap Equi...
COIN
PSHPUSD
Payship.org
NASDAQ
FDVZX
Bmo Managed Conservative...
NASDAQ
YDNT
LSE
SGFM
Granite 1s Gfam
NASDAQ
CAKDX
Canoe Global Equity Fund...
FX
BLRREFIN
Belarus Refinancing Rate
BITI
ITSTARN
ITCADZ ZKB C
NASDAQ
FCYMX
Bmo Canadian Smart Alpha...
TG
A5SA
Aston Martin Lagonda Glo...
USOTC
STPJF
Southern Pacific Resource (CE)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지